Christopher Haqq is VP at Atara Biotherapeutics, Inc. (ATRA). They have made 20 open-market trades across 1 company since 2015, most recently 2026-02-02.
CIK 0001604464
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 20 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRA | SELL · 10b5-1 | 2019-02-15 | 2019-02-19 | $39.59 | $31K | -5.7% | -1.3% | -42.1% |
| ATRA | SELL | 2019-02-11 | 2019-02-11 | $38.55 | $1.1M | -0.7% | +4.7% | -37.7% |
| ATRA | SELL | 2019-02-06 | 2019-02-08 | $38.62 | $956K | -1.5% | -4.3% | -29.7% |
| ATRA | SELL · 10b5-1 | 2018-11-15 | 2018-11-15 | $33.81 | $26K | +12.2% | +11.6% | +10.8% |
| ATRA | SELL | 2018-09-26 | 2018-09-27 | $43.08 | $582K | -9.6% | -21.4% | -16.2% |
| ATRA | SELL | 2018-09-24 | 2018-09-25 | $40.08 | $2.0M | -6.6% | -21.5% | -28.8% |
| ATRA | SELL · 10b5-1 | 2018-08-15 | 2018-08-16 | $37.54 | $29K | +13.8% | +11.6% | -3.5% |
| ATRA | SELL | 2018-05-15 | 2018-05-16 | $45.30 | $2.3M | +3.5% | -4.4% | -18.3% |
| ATRA | SELL | 2018-03-26 | 2018-03-27 | $39.78 | $1.4M | -6.3% | +10.7% | +7.3% |
| ATRA | SELL · 10b5-1 | 2017-11-15 | 2017-11-17 | $13.36 | $21K | -1.4% | +0.3% | +221.2% |
| ATRA | SELL | 2017-10-16 | 2017-10-17 | $14.35 | $86K | -7.8% | -1.7% | +86.8% |
| ATRA | SELL | 2017-09-15 | 2017-09-18 | $15.30 | $92K | +3.8% | -8.3% | -5.8% |
| ATRA | SELL | 2017-08-15 | 2017-08-17 | $14.75 | $112K | +11.1% | +14.8% | +3.7% |
| ATRA | SELL | 2017-07-17 | 2017-07-18 | $14.92 | $90K | -6.3% | -14.7% | -9.1% |
| ATRA | SELL | 2017-06-15 | 2017-06-16 | $12.65 | $76K | +12.5% | +23.0% | +20.7% |
| ATRA | SELL | 2017-05-15 | 2017-05-17 | $14.99 | $228K | -11.1% | -14.4% | -4.4% |
| ATRA | SELL | 2017-04-17 | 2017-04-19 | $17.28 | $104K | -9.2% | -18.3% | -14.6% |
| ATRA | SELL | 2017-03-15 | 2017-03-17 | $19.60 | $235K | -4.0% | -10.8% | -38.0% |
| ATRA | SELL | 2017-02-15 | 2017-02-16 | $15.49 | $236K | +6.5% | +37.1% | -4.5% |
| ATRA | SELL | 2017-02-09 | 2017-02-10 | $15.46 | $432K | -2.6% | +49.3% | +0.3% |
| ATRA | SELL | 2017-01-17 | 2017-01-18 | $14.27 | $86K | -13.9% | +6.1% | +23.8% |
| ATRA | SELL | 2016-12-15 | 2016-12-15 | $15.40 | $92K | -7.3% | -11.7% | +18.9% |
| ATRA | SELL | 2016-11-21 | 2016-11-22 | $17.85 | $252K | +9.0% | -18.5% | -12.6% |
| ATRA | SELL · 10b5-1 | 2016-11-15 | 2016-11-17 | $19.95 | $32K | +7.9% | -9.5% | -12.5% |
| ATRA | SELL | 2016-08-15 | 2016-08-17 | $22.32 | $30K | -12.1% | -13.5% | -13.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.